Valion Bio Inc (VBIO)

2026-08-17T09:21:46.000Z - 2 days ago

Valion Bio announces U.S. government-funded entolimod studies

2026-08-17T07:28:36.000Z - 2 days ago

Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier

Aug 14, 2026, 4:00 PM EDT - 4 days ago

Valion Bio Quarterly report: Q2 2026

Aug 14, 2026, 12:00 PM EDT - 4 days ago

Valion Bio Transcript: EGM 2026

Aug 13, 2026, 10:00 AM EDT - 5 days ago

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Aug 12, 2026, 9:29 AM EDT - 6 days ago

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

2026-07-22T11:50:09.000Z - 4 weeks ago

Valion Bio’s regulatory dossier for Entolimod accepted for review in Ukraine

Jul 22, 2026, 7:45 AM EDT - 4 weeks ago

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Jul 20, 2026, 1:28 PM EDT - 4 weeks ago

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

2026-07-17T20:10:42.000Z - 4 weeks ago

Valion Bio files to sell 29.41M shares of common stock, warrants

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

Valion Bio Registration statement: Registration filing

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

Valion Bio Proxy statement: Proxy filing

2026-07-14T11:55:36.000Z - 5 weeks ago

Valion Bio reports continued development of Entolimod program

Jul 14, 2026, 7:45 AM EDT - 5 weeks ago

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Jul 7, 2026, 8:00 AM EDT - 6 weeks ago

Valion Bio Proxy statement: Proxy filing

Jun 25, 2026, 7:45 AM EDT - 7 weeks ago

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

May 28, 2026, 1:00 PM EDT - 2 months ago

Valion Bio Transcript: AGM 2026

May 19, 2026, 4:38 PM EDT - 3 months ago

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

2026-05-14T22:26:28.000Z - 3 months ago

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

2026-05-14T21:41:38.000Z - 3 months ago

Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year

May 14, 2026, 4:31 PM EDT - 3 months ago

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

May 14, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Quarterly report: Q1 2026

May 14, 2026, 4:05 PM EDT - 3 months ago

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

May 11, 2026, 8:01 AM EDT - 3 months ago

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

May 6, 2026, 8:08 AM EDT - 3 months ago

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

2026-05-05T12:15:18.000Z - 3 months ago

Valion Bio receives first study protocol under agreement with NIAID

May 5, 2026, 8:00 AM EDT - 3 months ago

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

2026-05-04T20:42:49.000Z - 3 months ago

Valion Bio names Melinda Lackey as General Counsel

TCRT

May 4, 2026, 4:05 PM EDT - 3 months ago

Valion Bio Appoints Melinda Lackey as General Counsel

TCRT

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Valion Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:01 AM EDT - 4 months ago

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Apr 23, 2026, 4:05 PM EDT - 4 months ago

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Valion Bio Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Valion Bio Registration statement: Registration filing

Apr 1, 2026, 2:55 PM EDT - 4 months ago

Valion Bio Transcript: Emerging Growth Conference 91

Mar 31, 2026, 8:30 AM EDT - 5 months ago

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Mar 27, 2026, 11:30 AM EDT - 5 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Mar 26, 2026, 8:30 AM EDT - 5 months ago

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Valion Bio Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Valion Bio Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Valion Bio Earnings release: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 5 months ago

Tivic Reports Full Year 2025 Results

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Tivic Health CEO Letter to Shareholders

Mar 20, 2026, 3:35 PM EDT - 5 months ago

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Mar 12, 2026, 4:00 PM EDT - 5 months ago

Valion Bio Transcript: EGM 2026

Mar 4, 2026, 8:30 AM EST - 5 months ago

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Mar 4, 2026, 6:00 AM EST - 6 months ago

Valion Bio Slides: Investor presentation

Feb 18, 2026, 9:15 AM EST - 6 months ago

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Feb 9, 2026, 7:00 AM EST - 6 months ago

Valion Bio Proxy statement: Proxy Filing

Jan 28, 2026, 8:30 AM EST - 7 months ago

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Jan 26, 2026, 10:10 AM EST - 7 months ago

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Jan 22, 2026, 4:10 PM EST - 7 months ago

Valion Bio Transcript: Emerging Growth Conference 89

Jan 20, 2026, 5:50 PM EST - 7 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Jan 20, 2026, 7:00 AM EST - 7 months ago

Valion Bio Slides: Investor presentation

Jan 12, 2026, 4:30 PM EST - 7 months ago

Valion Bio Transcript: Investor Update

Jan 12, 2026, 9:00 AM EST - 7 months ago

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Jan 9, 2026, 7:00 AM EST - 7 months ago

Valion Bio Proxy statement: Proxy Filing

Jan 8, 2026, 8:30 AM EST - 7 months ago

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

Dec 29, 2025, 7:00 AM EST - 8 months ago

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 8 months ago

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 8 months ago

Valion Bio Proxy statement: Proxy Filing

Dec 11, 2025, 9:45 AM EST - 8 months ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Nov 18, 2025, 8:30 AM EST - 9 months ago

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Nov 14, 2025, 4:30 PM EST - 9 months ago

Tivic Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 9 months ago

Valion Bio Earnings Call Transcript: Q3 2025

Nov 14, 2025, 4:30 PM EST - 9 months ago

Valion Bio Quarterly report: Q3 2025

Nov 14, 2025, 4:30 PM EST - 9 months ago

Valion Bio Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

Nov 10, 2025, 9:00 AM EST - 10 months ago

Tivic Expands Intellectual Property Portfolio

Nov 6, 2025, 9:30 AM EST - 10 months ago

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Oct 22, 2025, 2:00 PM EDT - 10 months ago

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Valion Bio Registration statement: Registration Filing

Sep 25, 2025, 11:25 AM EDT - 11 months ago

Valion Bio Transcript: Emerging Growth Conference 2025

Sep 22, 2025, 8:30 AM EDT - 11 months ago

Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

Sep 10, 2025, 8:30 AM EDT - 1 year ago

Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

Aug 29, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Aug 20, 2025, 8:30 AM EDT - 1 year ago

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Aug 15, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Tivic Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Announces 2025 Annual Meeting of Stockholders

Jun 11, 2025, 1:30 PM EDT - 1 year ago

Valion Bio Transcript: Life Sciences Virtual Investor Forum

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

May 22, 2025, 1:00 PM EDT - 1 year ago

Valion Bio Transcript: Sidoti May Micro-Cap Virtual Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

May 14, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

May 13, 2025, 8:30 AM EDT - 1 year ago

Tivic Expands VNS Intellectual Property Portfolio

May 9, 2025, 8:30 AM EDT - 1 year ago

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast